Maintenance Niraparib, Given at Individualized Starting Dose, Improves PFS in Chinese Patients With Ovarian Cancer
November 21st 2020
November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.